08:44 AM EST, 12/19/2024 (MT Newswires) -- Bio-Path Holdings ( BPTH ) said Thursday that results from its preclinical trials of BP1001-A showed "enhanced insulin sensitivity," confirming it as a "potential" treatment for obesity and metabolic diseases in type 2 diabetes patients.

BP1001-A helps lower blood glucose levels in type 2 diabetes patients as it reduces growth factor receptor-bound protein 2, or Grb2, to raise insulin sensitivity, the company added.

The trial results showed that BP1001-A lowered Grb2 protein expression in myoblast cells and increased phosphorylated AKT and phosphorylated FOXO-1 levels in myoblast and hepatoma cells, the company said.

Bio-Path ( BPTH ) said it has started animal trials to confirm the efficacy of BP1001-A to treat obesity and related metabolic diseases in type 2 diabetes patients and if successful, it anticipates starting a first-in-human phase 1 clinical study next year.

Shares of the company surged over 230% in recent Thursday premarket activity.

Price: 2.21, Change: +1.54, Percent Change: +230.34